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BACKGROUND: The development of targeted therapies has created a pressing clinical need for molecular characterisation of cancers.
In this retrospective study, high-resolution melting analysis (HRMA) was validated and implemented for screening of 164 colorectal
cancer (CRC) patients to detect KRAS hot-spot mutations and to evaluate its prognostic value. Direct sequencing was used to
confirm and characterise HRMA results.
METHODS: After establishing its sensitivity, HRMA was validated on seven cell lines and inter- and intra-variation were analysed. The
prognostic value of KRAS mutations in CRC was evaluated using survival analysis.
RESULTS: HRMA revealed abnormal melting patterns in 34.1% CRC samples. Kaplan–Meier survival curves revealed a significantly
shorter overall (OS) and disease-free survival (DFS) for CRC patients harbouring a KRAS mutation. In the Cox regression analysis,
only when colon and rectal cancer were analysed separately, KRAS mutation was a negative predictor for OS in patients with rectal
cancer and DFS in those with stage II colon cancer.
CONCLUSIONS: HRMA was found to be a valid screening method for KRAS mutation detection. The KRAS mutation came forward as a
negative predictive factor for OS in patients with rectal cancer and for DFS in stage II colon cancer patients.
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Among the most daunting challenges facing oncology today is that
of patient selection, particularly for therapy with molecularly
targeted agents (Jimeno et al, 2009). Hence, robust prognostic
markers and markers predictive for treatment response, resistance
and toxicity are necessary.
For example, the epidermal growth factor receptor (EGFR) has
become an important target for treatment of metastatic colorectal
cancer (mCRC), specifically with the monoclonal antibodies
(mAbs) cetuximab and panitumumab (Heinemann et al, 2009).
Several reports indicate that an increased gene copy number of
EGFR or mutations of genes responsible for downstream signal-
ling, especially KRAS, are important determinants of response or
resistance to anti-EGR antibodies (Heinemann et al, 2009).
KRAS is part of a group of three homologous oncogenes and
encodes a small 21kDa protein (p21Ras) involved in the
transduction of external stimuli to effector molecules across
plasma membranes, downstream from the EGFR. This protein has
intrinsic guanosine triphosphatase (GTPase) activity, allowing
inactivation after signal transduction in the normal cellular
environment. Somatic point mutations of KRAS occurring early
in CRC tumourigenesis are thought to abolish GTPase activity,
leading to a constitutive activation of KRAS, and inevitably to
increased and unregulated cellular proliferation and malignant
transformation (Adjei, 2001; Conlin et al, 2005). Oncogenic
mutations of the KRAS gene are observed in B40% of sporadic
CRC, and up to 90% of these mutations are detected in codons 12
and 13 and less frequently also in codons 61 and 63 (Heinemann
et al, 2009). The functions of KRAS support its putative predictive
and prognostic role in CRC, and several studies have been
performed trying to illustrate this (Graziano and Cascinu, 2003).
With respect to its predictive role, several retrospective analyses
of tumour samples in CRC patients receiving anti-EGFR antibody
treatment have shown that patients with mutated KRAS did not
benefit from anti-EGFR therapy (Lievre et al, 2006; Amado et al,
2008). Based on systematic reviews of the relevant literature, the
American Society of Clinical Oncology suggested, in a Provisional
Clinical Opinion in 2009, that when KRAS mutations in codon 12
or 13 were detected in patients with mCRC, such patients should
not receive anti-EGFR antibody therapy as part of their treatment
(Allegra et al, 2009). The European Medicines Agency has also
recognised these findings, and indeed also restricts the use of anti-
EGFR antibody therapy only to CRC patients with wild-type (wt)
KRAS tumours (Javle and Hsueh, 2009).
With respect to its prognostic role in CRC, literature data on the
impact of KRAS mutations on outcome has been controversial,
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sincluding in those with node-negative disease, for whom a
discriminator would be most useful (Jimeno et al, 2009, and as
reviewed by Anwar et al, 2004; Klump et al, 2004; Locker et al, 2006).
In addition, with the advent of personalised medicine, there is a
compelling need for rapid and accurate methods for detection of
nucleic acid sequencing changes, such as, KRAS mutations, in
clinical specimen (Krypuy et al, 2006). A wide range of mutation
detection techniques exists, of which sequencing has been the gold
standard (Krypuy et al, 2006). However, its limited sensitivity, high
costs and long turnaround time have prompted the development of
alternative methods for routine clinical testing that have greater
diagnostic practicality for somatic mutation detection (Do et al,
2008). High-resolution melting analysis (HRMA) is a recently
developed methodology that has enormous potential for the
detection of DNA sequence changes (Do et al, 2008). Mutation
scanning with HRMA is based on the dissociation behaviour of
DNA when exposed to an increasing temperature, in the presence
of intercalating fluorescent dyes. The HRMA melting profile gives
a sequence-related pattern, allowing discrimination between wt
sequences and homozygote–heterozygote variants (Giuliani et al,
2008). Owing to its high sensitivity, HRMA seems to present a
more sensitive approach, allowing rapid, accurate and reliable
detection of a minimal fraction of mutated cells in tumoral tissue
(Giuliani et al, 2008; Kramer et al, 2009).
The aim of this study was to validate and implement HRMA to
detect KRAS mutations in formalin-fixed paraffin-embedded
(FFPE) CRC samples. In addition, the prognostic value of KRAS
mutation was evaluated in a population of CRC patients.
MATERIALS AND METHODS
Samples and DNA extraction
Tissue samples were obtained from 164 sporadic CRC patients
treated at the Antwerp University Hospital in Edegem and the
St Augustinus Hospital in Wilrijk. DNA was extracted from FFPE
tissue blocks as described previously (Deschoolmeester et al,
2006). DNA concentration and purity was defined using the
Nanodrop 1000 (Isogen, Sint-Pieters-Leeuw, Belgium). Micro-
satellite instability (MSI) status was defined previously
(Deschoolmeester et al, 2008).
Assay design and PCR conditions
Primers were designed to span codons 12 and 13 of the KRAS gene.
Primers for the 114-bp amplicon of exon 2 were 50-GCCTGCTG
AAAATGACTGAA-30 (forward) and 50-TTGGATCATATTCGTCC
ACAA-30 (reverse). The reaction mixture was made up using
2.5  LightScanner Mastermix (Idoha Technology Inc., Salt Lake
City, UT, USA), 1.65mM MgCl2,5mM of each sense and antisense
primer, 4% (v/v) DMSO, 2ml genomic DNA or 20ng cell line DNA
and water in a total volume of 10ml.
The PCR cycling was performed on the Rapid Cycler Instrument
2 (Idoha Technology Inc.), whereas HRMA was performed on the
HR/1 High-Resolution Melter (Idoha Technology Inc.) and
measured by the HR/1 Instrument Control software. The 114-bp
amplicon was run according to the following conditions: one cycle
of 951C for 30s and 45 cycles in the following sequence: 951C for
10s, 651C for 10s and 741C for 2s. The results were analysed using
the HR/1 Melt Analysis Tool software (Idoha Technology Inc.).
HRMA sensitivity testing
High-resolution melting analysis sensitivity testing was conducted
by mixing a series of dilutions of 50, 25, 12.5, 6 and 3% of mutant
KRAS DNA from A549 (G12S, homozygous mutation in codon 12)
within wt KRAS DNA from CAL27. In addition, these cell lines
were also used as positive and negative controls.
Subsequently, the HRMA of KRAS mutations was validated in a
set of DNA obtained from several cell lines (Table 1) with or
without a known KRAS mutation.
DNA sequencing
After HRMA, the PCR products with a deviating pattern were
separated on a 2% low melting point agarose gel (Ultra Pure, Gibco
BRL, Merelbeke, Belgium) during 60min on 50V. After separation,
the desired bands were excised from the gel and the DNA was
isolated and purified using spin procedure for agarose gels
(GenElute Gel Extraction Kit, Sigma, Bornem, Belgium). The
purified PCR product was then used as template in cycle
sequencing using the Big Dye Terminator v1.1 kit (Applied
Biosystems, Foster City, CA, USA). The reaction mixture consisted
of 1.1  sequencing buffer, 0.2ml Big Dye mix, 625nM primer and
1ml of cleaned template in a total volume of 4ml. The forward and
reverse reactions were run on a Rapid Cycler Instrument 2 (Idoha
Technology Inc.) according to the following protocol: one cycle of
951C for 30s and 25 cycles in the following sequence: 961C for 10s,
501C for 5s and 601C for 2min. The sequencing reactions were run
on a 3130 XL Genetic Analyzer (Applied Biosystems). Sequencing
data was analysed using SeqScanner software v1.0 (Applied
Biosystems).
Statistical analysis
Prognostic relevance of KRAS mutation was assessed by survival
analysis. The index date for survival time calculation was defined
as the date of diagnostic confirmation for CRC. The months of
observation (overall survival (OS) time) were calculated from the
index date to the date of last information/death. For disease-free
Table 1 Characteristics of the human cell lines used for sensitivity testing and validation of the HRM analysis technique for KRAS mutation detection
Cell line Origin (human) Mutation Reference
A549 Lung carcinoma KRAS exon 2: G12S homozygous Krypuy et al, 2006
CAL27 Head and neck carcinoma
ECV304 Bladder carcinoma
SQD9 Head and neck squamous
carcinoma
NCI-H292 Lung carcinoma
HCT116 Colon carcinoma KRAS exon 2: G13D heterozygous Krypuy et al, 2006; Simi et al, 2008
MDA-MB231 Breast carcinoma KRAS exon 2: G13D heterozygous Cosmic data set, Welcome Trust Sanger Institute,
2009: http://www.sanger.ac.uk/perl/genetics /CPG/
core_line_viewer?action¼sample&id¼909960
Abbreviation: HRM¼high-resolution melting.
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ssurvival (DFS) time, the months of observation were calculated
from the index date to the first date of progression or the date of
last information. Survival curves were determined by using the
Kaplan–Meier method and were analysed by using the log-rank
test.
Possible associations between KRAS mutation and clinicopatho-
logical parameters of CRCs were investigated using the w
2-test or
Fisher’s exact test (when appropriate) for categorical variables and
using Student t-test or Mann–Whitney U-test (when appropriate)
for continuous variables. To assess the independent prognostic
contribution of KRAS mutation, a multiple Cox regression analysis
was conducted. In addition, a stepwise backward binary logistic
regression was performed to identify which of the clinicopatho-
logical parameters had the strongest impact on survival in CRC.
All analyses were conducted using SPSS (version 16.0, SPSS Inc.,
Brussels, Belgium). Significance for all statistics was recorded if
Po0.05 (two tailed).
RESULTS
Patient characteristics
Of the 164 CRC patients from whom tumour tissue could be
obtained, most (but not all) clinical data were retrieved. Most
tumours were located in the distal part of the large bowel (68.3%),
and most patients had a stage II or III disease. Further details on
these patients are summarised in Table 2.
Assay sensitivity testing
Sensitivity of the melting profile in discriminating different
percentages of mutated alleles was initially evaluated by using
serial dilutions of mutated DNA, derived from a cultured cell line
with a known KRAS mutation, variably mixed with wt DNA
obtained from a wt cell line. A549 DNA (G12S, homozygous
mutation in codon 12) was mixed with wt CAL27 DNA in
proportions of 50, 25, 12.5, 6 and 3%. The difference plot
(Figure 1A) shows that HRMA was able to identify the presence
of an abnormal profile in all dilutions, allowing the clear
identification of mutated alleles. In addition, dideoxy sequencing
analysis was performed on the 12.5, 6 and 3% dilutions using the
same PCR product after melting analysis (Figure 1B). The results
of HRMA were only confirmed for the 12.5% dilution by
sequencing analysis in both the forward and the reverse primer
set. In the case of 6% (for forward primer) and 3% (both forward
and reverse primer) mutant DNA in wt DNA, sequencing analysis
was not able to incontestably confirm the presence of mutant
alleles, as seen by the nucleotide sequence generated by the
sequencing software.
Assay validation
Cancer cell lines with or without a known KRAS mutation (Table 1)
were first used to test the HRMA methodology. The HRMA was
able to discriminate between the wt DNA and the different
mutations present in the mutant cell line DNA. As seen in the
melting (Figure 2A) and derivative plot (Figure 2B), HCT116,
MDA-MB-231 and NCI-H292 showed typical heteroduplex melting
patterns and were readily distinguishable from the wt cell lines
CAL27 and ECV304. The lung cancer cell line A549 has a
homozygous mutation (Table 1) and, as expected, it showed a
similar shape to the wt pattern but with earlier melting of the
amplified product, which is consistent with the lower thermal
stability of AT base pairs relative to GC base pairs. Furthermore,
dideoxy sequencing analysis confirmed the HRMA results in all
cases (data not shown). In addition, an inter- and intra-variation
analysis was performed on three different days in four different cell
lines (A549, CAL27, ECV304 and SQD9). The results showed that
inter- and intra-variation was present and could hamper the
interpretation of the results (Figure 3). However, within one
experiment, it was still possible to discriminate between DNA of
the mutant cell line and that of the three wt cell lines (Figure 4).
These results indicate that it is necessary to include positive
(mutant) and negative (wt) controls in each experiment. In
addition, owing to the inter-variation, it is inadvisable to compare
plots generated on different days.
KRAS mutation detection in CRC samples
The 114-bp amplicon was used to screen for KRAS mutation in
codons 12 and 13 of 164 sporadic CRC samples. Aberrant curves
were detected in 56 of 164 (34.1%) samples assayed. A total of 49
samples were confirmed by sequencing analysis and additionally
revealed the actual mutation. Seven samples could not be
confirmed by sequencing analysis, either due to lack of material
or due to inconclusive results. As not all HRMA-positive samples
could be confirmed by sequencing, the percentage of established
KRAS mutations in CRC is reduced to 29.9%. As shown in Figure 5,
23.2% of the samples showed mutations in codon 12, whereas only
in 6.7% of the samples, the mutations was found in codon 13.
Among the different mutations, G12D substitution was the most
prevalent (40.8%), followed by G13D, G12V and G12C. The other
mutations were less frequently detected (Figure 5).
Table 2 Clinical characteristics of patients analysed for the overall
population and for patients with colon cancer and rectal cancer separately
Colon Rectum
Overall
population
Patient characteristics
Total no. of patients 103 50 164
Median age (years) 66±13 63±12 65±13
Sex
Male 51 (49.5%) 24 (48.0%) 80 (48.2%)
Female 51 (49.5%) 26 (52.0%) 78 (48.8%)
Location
Proximal — — 45 (27.4%)
Distal — — 112 (68.3%)
Grade of differentiation
Poor 10 (9.7%) 3 (6.0%) 14 (8.5%)
Moderate 34 (33.0%) 18 (36.0%) 55 (33.5%)
Well 56 (54.4%) 28 (56.0%) 87 (53.0%)
Stage
I 11 (10.7%) 8 (16%) 20 (12.2%)
II 43 (41.7%) 20 (40.0%) 69 (42.1%)
III 31 (30.1%) 14 (28.0%) 45 (27.4%)
IV 14 (13.6%) 8 (16.0%) 22 (13.4%)
Therapy
Neo-adjuvant
Yes 1 (1.0%) 19 (38.0%) 22 (13.4%)
No 89 (86.4%) 24 (48.0%) 120 (73.2%)
Adjuvant
Yes 35 (34.0%) 16 (32.0%) 57 (34.8%)
No 63 (60.2%) 27 (54.0%) 92 (56.1%)
MSI status
MSI 13 (12.6%) 0 (0.0%) 14 (8.5%)
MSS 90 (87.4%) 50 (100%) 150 (91.5%)
Abbreviations: MSI¼microsatellite instability; MSS¼microsatellite stability. In 11
patients the actual location of the tumour was not specified; not all clinical
characteristics were available for each patient.
Prognostic value of KRAS mutations in CRC using HRMA
V Deschoolmeester et al
1629
British Journal of Cancer (2010) 103(10), 1627–1636 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sPrognostic relevance of KRAS mutation in CRC
Follow-up for OS and DFS was available for 153 and 139 CRC
patients, respectively. At the end of the observation period, 58
patients (37.9%) were deceased and 37 patients (27.0%) experi-
enced a recurrence of the tumour. All deaths were cancer related.
The median follow-up for OS and DFS was 4.7 and 4.5 years,
respectively.
In the overall study population, the presence of a KRAS
mutation was significantly associated with proximal location of
the tumours (P¼0.05). Age, gender, stage, MSI status and grade of
differentiation did not seem to be correlated to the occurrence of a
KRAS mutation. Patients with a KRAS mutation showed a shorter
OS (HR, 1.70; P¼0.05) and DFS (HR, 2.03; P¼0.04) compared
with patients with wt KRAS in the Kaplan–Meier analysis
(Figure 6). The data were even more significant for those with a
G12C mutation (P¼0.04 and P¼0.006 for OS and DFS,
respectively), but the number of patients with a G12C mutation
was extremely small (n¼6). Both patients with an MSI tumour
(P¼0.05) and those with an early-stage tumour had a significantly
longer OS, whereas early-stage tumours also had a significantly
longer DFS (Po0.001). When entered into a multiple Cox
regression analysis adjusting for possible important confounding
factors, early stage was still significantly correlated with a longer
OS (HR, 1.99; Po0.001) and DFS (HR, 2.35; Po0.001), whereas age
only had a significant impact on OS (HR, 1.04; Po0.001). The
effect of KRAS mutation on survival could not be confirmed in the
multiple Cox regression analysis for the overall population.
However, KRAS mutation was still a negative predictor of survival
when analysed separately for rectal cancer patients (Table 3).
As mentioned earlier, the value of KRAS mutations to define
who should benefit from adjuvant chemotherapy and who should
not is especially important for stage II CRC. Therefore, a stage-
dependent survival analysis was performed, which indicated that
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Figure 1 (A) Difference plot generated with serial dilutions of DNA from a mutated cell line in wild-type DNA to assess HRMA sensitivity.
(B) Electropherograms of sequencing analysis for the same serial dilutions. Only 12.5% could be incontestably confirmed by sequencing analysis.
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sstage II patients with a KRAS mutation had a trend towards a
worse DFS (HR, 3.06; P¼0.09), whereas there was no significant
association with a worse OS (HR, 1.97; P¼0.23).
Interestingly, when stage II colon and rectal tumours were
analysed separately, only the presence of a KRAS mutation in colon
cancers was associated with a trend towards a worse DFS
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Figure 3 Inter- and intra-variance analysis of four different cell lines (A: A549, B: CAL27, C: ECV304 and D: SQD9) on 3 different days.
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Figure 4 Inter- and intra-variation analysis in four different cell lines (three wild type: ECV304, CAL27 and SQD9; one mutant: A549) on 3 consecutive
days (A: day 1, B: day 2 and C: day 3). Within each replicate of the same experiment, the mutant cell line (A549) is clearly discriminated from the three
wild-type cell lines.
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Figure 6 Kaplan–Meier survival analysis for KRAS mutation in CRC of the overall population (A) and of stage II patients in particular (B) for both overall
and disease-free survival. Significance was calculated using log-rank statistic.
Table 3 Survival analysis (univariate and Cox regression) for the presence of a KRAS mutation in the overall population and for colon cancer and rectal
cancer separately
Colon Rectum Overall population
n HR 95% CI P-value n HR 95% CI P-value n HR 95% CI P-value
Univariate analysis
OS 100 1.26 0.65–2.45 0.48 47 4.20 1.56–11.27 0.004 153 1.70 0.99–2.91 0.05
DFS 90 2.17 0.99–4.84 0.05 43 1.97 0.59–6.58 0.27 139 2.03 1.05–3.949 0.04
Cox regression
OS 90 1.18 0.58–2.39 0.62 39 5.23 1.13–24.18 0.04 130 1.39 0.85–2.64 0.26
DFS 85 1.78 0.76–4.17 0.17 36 1.84 0.21–15.77 0.57 129 1.59 0.81–3.15 0.19
Abbreviations: 95% CI¼95% confidence interval; DFS¼disease-free survival; HR¼hazard ratio; n¼number of cases analysed; OS¼overall survival.
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regression analysis (HR, 4.163; P¼0.07).
DISCUSSION
In the era of targeted therapy for cancer, molecular diagnosis of
particular genetic markers in tumours enables a more individua-
lised treatment of patients, as was recently shown for KRAS
mutation status and response rate to anti-EGFR therapy in CRC
(Pichler et al, 2009).
Although it has now been well established that KRAS mutation is
a negative predictor for response to anti-EGFR therapy (Allegra
et al, 2009; Balko and Black, 2009; Baynes and Gansert, 2009; Javle
and Hsueh, 2009; Jimeno et al, 2009; Kohne and Lenz, 2009;
Loupakis et al, 2009; Peeters et al, 2009; Saif and Shah, 2009),
the prognostic role of KRAS mutations in CRC is still unclear
(as reviewed by Anwar et al, 2004; Klump et al, 2004; Locker et al,
2006).
Given the potential impact of KRAS mutation detection for CRC
prediction and prognosis, a reliable diagnostic test may affect
future therapeutic decision making. In this study, it was
demonstrated that HRMA is a reliable and sensitive technology
for KRAS mutation detection. First, a cell-line-based model system
was used to establish and optimise the KRAS mutation HRMA.
A relative short amplicon (114-bp) was used, as it has been stated
that amplicon length could influence the sensitivity of genotyping
(Krypuy et al, 2006; Pichler et al, 2009). Shorter amplicon lengths
have given better resolution of genotypes and increased the
sensitivity of mutation detection, even down to 1% mutated cell
DNA (Pichler et al, 2009). Our experiments on reconstituted
samples, obtained by serial dilutions of a mutated cancer cell line
and normal DNA, indicated the possibility of identifying at least
3% of mutated alleles in a background of wt DNA, which was the
smallest dilution tested. This theoretical sensitivity seems well
suited for detecting even a limited percentage of mutated alleles in
a heterogeneous sample, as obtained from FFPE CRC tissues
(Giuliani et al, 2008). These results are in line with several other
studies which found that HRMA could detect 5% mutated cell
DNA in a background of wt DNA (Krypuy et al, 2006; Do et al,
2008; Simi et al, 2008; Pichler et al, 2009). In comparison to
sequencing analysis, HRMA seems to be more sensitive in this
study, as sequencing analysis had a detection limit of 12.5%
mutated alleles in a background of wt DNA. This is in agreement
with the literature, as sequencing requires mutant copies to have a
concentration that is at least 20–50% of any accompanying
wt sequences (Ogino et al, 2005; Jimeno et al, 2009; Pichler et al,
2009).
Next, HRMA was validated in a set of DNA obtained from
several cell lines (Table 1) with or without a known KRAS
mutation. As reported by others (Krypuy et al, 2006; Simi et al,
2008), the heterozygous and homozygous mutations in HCT116,
MDA-MB-231 and A549 could be detected with HRMA. In
addition, a heterozygous KRAS mutation (G12S) in NCI-H292
was detected by HRMA. These results were confirmed by
sequencing analysis. It might be possible that the NCI-H292 cell
line acquired a KRAS mutation during prolonged cell culture.
Therefore, the KRAS status needs to be examined in an
independent NCI-H292 cell line to definitively confirm the
presence of the heterozygous KRAS mutation. As mentioned in
several studies (Krypuy et al, 2006; Do et al, 2008; Pichler et al,
2009), the presence of unspecific PCR products, primer dimers or
differing salt or inhibitor concentrations may increase the spread
of wt curves. Consequently, it is critical to melt highly specific PCR
products. Subsequently, this study showed that inter- and intra-
variation was present and could hamper the interpretation of the
results on HRMA. However, within one experiment, it was still
possible to clearly discriminate mutated samples from wt samples.
The KRAS mutations were detected and confirmed by sequen-
cing in 49 of 164 (29.9%) CRC samples. This is in agreement with
the literature in which KRAS mutation frequencies range from 30
to 50% (Jimeno et al, 2009; Peeters et al, 2009). The G/A transitions
and G/T transversions were identified as the most frequently found
type of KRAS mutation, as described by various studies (Samowitz
et al, 2000; Bazan et al, 2005; Poehlmann et al, 2007; Neumann
et al, 2009). Codon 12 harboured 23.2% of the point mutations
detected, with the G12D mutation, in which glycine is replaced by
aspartic acid, the most prevalent type (40.8%). These results are
confirmed by Simi et al (2008). Although all positive sequencing
results were detected by HRMA, some HRMA-positive samples
could not be confirmed by sequencing. This might be explained by
the fact that adverse effects of formalin fixation on DNA or Taq
polymerase errors can cause PCR artefacts during amplification
(Srinivasan et al, 2002; Do et al, 2008; Pichler et al, 2009).
Unfortunately, fresh frozen tissue was not available for comparison
to confirm this hypothesis. Another possibility is that some
samples contained levels of mutation below the sensitivity of
sequencing detection as a result of low percentage of tumour in the
sample or genetic heterogeneity within the tumour (Do et al, 2008).
However, in our HRMA, no correlation was found between low
DNA concentrations and/or purity and unconfirmed positive
samples. In addition, all positive samples were repeated by
independent amplification to avoid false-positive results due to
errors introduced by Taq polymerase.
It has been known that KRAS point mutations are extremely
infrequent in sporadic MSI-H tumours (Ionov et al, 1993;
Salahshor et al, 1999; Samowitz et al, 2001; Zhao et al, 2008).
However, in several recent reports, it has been shown that the
occurrence of mismatch repair (MMR) gene mutations at an early
stage might be significant in tumourigenesis through KRAS
mutation in MSI-H CRC. It still remains enigmatic why only the
mismatch mutL homologue 1 (MLH1) mutation correlates with
KRAS mutation, but MLH1 promoter methylation does not, in
spite of equally defective MMR leading to a mutator phenotype
(Jass, 2002; Zhao et al, 2008; Kumar et al, 2009). In this study,
KRAS mutation was found in only one MSI-H sample, which might
be explained by the fact that our samples are derived from
sporadic CRC in which MLH1 promoter methylation is believed to
be the main route of tumourigenesis. The KRAS mutation was
associated with proximal location of the tumour. These results are
confirmed by others (Elnatan et al, 1996; Samowitz et al, 2000;
Andreyev et al, 2001; Oliveira et al, 2007; Ogino et al, 2009b).
Kaplan–Meier survival analysis of the entire study population
revealed a significantly shorter OS and DFS for CRC patients
harbouring a KRAS mutation. In Cox regression, significance of
KRAS mutation as a predictor of survival was lost. When colon
tumours and rectal tumours were analysed separately, the presence
of a KRAS mutation was associated with a worse DFS for colon
cancers and a worse OS for rectal tumours in univariate analysis. In
Cox regression, only the results for rectal cancer were maintained.
Stage-dependent survival analysis was performed, in particular
for stage II, as the value of KRAS mutations to define who should
receive adjuvant chemotherapy and who should not is especially
important for these patients. In addition, Roth et al (2009)
suggested that molecular markers in colon cancer have a stage-
specific prognostic value and that different stages might represent
different diseases rather than sequential steps in the evolution of a
single disease. Kaplan–Meier survival curves revealed a trend
towards a worse DFS for stage II patients harbouring a KRAS
mutation. When analysed separately for stage II colon cancer and
stage II rectal cancer, this trend was only seen in colon cancer
patients, and the negative impact was maintained in the Cox
regression analysis.
Previous reports have shown conflicting results concerning the
relation with prognosis (Laurent-Puig et al, 1992; Andreyev et al,
2001; Losi et al, 2004; Roth et al, 2010). These contradictions are
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but may also be due to the role that stage may have on the effect of
genetic factors on prognosis (Cerottini et al, 1998). In addition,
recent studies suggest that different KRAS gene mutations have
different impacts on outcome (Cerottini et al, 1998; Andreyev et al,
2001). In this study, only G12C substitutions were significantly
associated with a worse OS and/or DFS in the overall population,
although caution is mandatory because some mutations were only
found once. These results are in agreement with Moerkerk et al
(1994) who identified G/T and G/C transversions in codon 12 to
be associated with advanced disease. Finkelstein et al (1993)
established a correlation between G12D mutation and haemato-
genous metastasis at the time of diagnosis. In the same study,
G12V and G13D were found to have no impact on survival. In
contrast, prognostic significance for KRAS codon 13 mutations has
been reported in CRC (Pajkos et al, 2000; Samowitz et al, 2000;
Bazan et al, 2002). The RASCAL II study demonstrated a
significant influence on survival of only one mutation, G12V,
especially in Dukes C patients (Andreyev et al, 1998, 2001). This
was not confirmed in our study, although more G12V than G12C
mutations were found. Further analyses are clearly necessary.
In contrast, recent analyses from the CALGB89803 (stage III)
and PETACC-3 study (stage II and III) trials did not demonstrate
KRAS mutation to be a prognostic marker for colon cancer
patients treated with adjuvant 5FU-based chemotherapy (Tejpar
et al, 2010). These results are in contrast to those of the RASCAL
studies and also to the trend towards a worse DFS in stage II colon
cancer patients found in this study. Roth et al (2010) and Ogino
et al (2009a) argue that the meta-analyses of Andreyev et al (1998,
2001) substantially suffered from publication bias and possibly
resulted in false-positive results because of the number of subset
analyses. However, the patients enroled in the randomised trials
(GALGB89803 and PETACC-3) may differ from the population at
large, as they are selected on the basis of eligibility criteria.
Recently, the MRC COIN trial could not find an improvement in
the OS or progression-free survival of mCRC patients treated with
cetuximab, but they did show that NRAS, KRAS and BRAF were
strongly prognostic regardless of cetuximab treatment (Maughan
et al, 2010).
The differences between studies might also be related to the
retrospective nature of the analyses of single-arm investigations
performed in small and often heterogeneous cohorts of patients in
which rectal and colon tumours have been examined together. In
addition, patients may not have been stratified by stage, gender or
age. Thus, many have been statistically underpowered to provide
meaningful results (Tejpar et al, 2010). However, in this study,
although retrospective in nature, colon and rectal tumours were
analysed separately and patients were stratified according to stage.
In addition, a lack of standardisation of methodologies for marker
assessment has resulted in data that are not comparable, and not
all mutations within a given gene are always screened for, possibly
leading to underestimation of the role of KRAS mutations (Tejpar
et al, 2010). Larger prospective studies are required to provide a
decisive answer, if possible.
The predictive value of KRAS, that is, whether or not patients
will respond to anti-EGFR therapy, could not be analysed in this
retrospective study, as anti-EGFR mAbs were not available for
treatment of these patients at the time. In addition, only 13.7% of
the study population had distant metastases, the setting for which
treatment with anti-EGFR therapy has been approved (Allegra
et al, 2009; Heinemann et al, 2009; Jimeno et al, 2009). However, of
the mCRC patients in our study population, 50% had a KRAS
mutation, which would render anti-EGFR therapy ineffective. This
underlines the importance of KRAS mutation analysis.
In conclusion, HRMA was found to be a fast, efficient and
reproducible screening method for KRAS mutation detection,
using which also DNA from FFPE tissues can be tested. However,
further validation studies are needed before this technique can be
used in the clinical setting. The KRAS mutation in our retro-
spective study came forward as a negative predictive factor for OS
in patients with rectal cancer and for DFS in stage II colon cancer
patients (trend). Our data support the idea that evidence is
accumulating that poor outcome could be linked to specific
mutations and that specific gene mutations might have an impact
on patient selection for adjuvant treatment.
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